Objective: To estimate the willingness to pay for a new chemotherapy, raltitrexed (Tomudex(TM) ) over conventional therapy with fluorouracil plus leucovorin (FU-LV) from the perspective of patients with advanced colorectal cancer. The study was part of the product's reimbursement application in...